Lupus Therapeutics

06/15/2023

Lupus Therapeutics, an affiliate of Lupus Research Alliance, recently held its second annual Lupus Clinical Investigators Network (LuCIN) Community Meeting.

The highly successful meeting brought together dozens of clinical investigators from our premier LuCIN trials network, study coordinators, people with lupus, research and industry partners for networking, collaboration, and engagement. Key panel discussions spotlighted the future of cell therapies, improving recruitment in clinical trials, and catalyzing treatment development with the multi-faceted nature of lupus.

Watch highlights!

01/18/2023

We’re pleased to share that Stacie J. Bell, PhD has been appointed Executive Vice President of Lupus Therapeutics (LT), LRA’s affiliate organization formed to advance lupus clinical research by finding more effective and safer treatments for people living with lupus.

“I am excited about working with the lupus community to bring together diverse stakeholders, drive patient engagement, and accelerate clinical research for this disease which requires many individualized treatments. I am honored to further the mission of Lupus Therapeutics.”

Read more about Stacie J. Bell: bit.ly/SJB-LT

10/05/2020

How can YOU make a difference in the lives of those with lupus? Find out the answer to your questions and more at our Lupus Clinical Trials Redefined Virtual Fair on 10/17 from 10am to 1:00pm ET!

Hosted by Lupus Therapeutics and Lupus Research Alliance, the Fair will feature a panel including researchers and a person with who has been in a trial. In the exhibit area, visitors can talk to trial site staff about the specific trials they are conducting.

Register now: lupustrialsoct.vfairs.com

10/24/2019

Who are our PALS? PALS focuses on reaching diverse populations to improve their knowledge and awareness of trials, and to promote enrollment by people living with lupus.

“Under-enrollment in lupus trials is critical because of the heterogeneity of the disease. There is no one test to evaluate activity per se—and symptoms that effect patients most, like severe fatigue at a level that disrupts daily life, aren’t yet measurable in a standardized, scientific way,” said Caroline Donovan, Manager of Patient Engagement.

Read more on how this important initiative has tremendous potential to advance the mission of Lupus Therapeutics: bit.ly/PALS_Involvement

Many dynamics of lupus contribute to the fact that its complexities have eluded the scientific community—but new hope may come from patients themselves. This is why Lupus Therapeutics piloted the Patient Advocates for Lupus Studies (PALS) program in the Summer of 2019. PALS focuses on reaching div...

10/23/2019

“We’re on a mission to accelerate drug discovery for all people living with lupus.” said Albert Roy, Executive Director of Lupus Therapeutics. Learn more on how Lupus Research Alliance affiliate Lupus Therapeutics is Shifting the Paradigm —going bold and thinking big—and shifting the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials.

Read more:

The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affi...

10/07/2019

The Lupus Clinical Investigators Network (LuCIN) is our North American-based lupus clinical trials network composed of fifty-seven (57) of the most reputable academic research medical centers in the world. LuCIN brings together the biopharmaceutical industry and lupus experts to evaluate the safety and effectiveness of new therapies for lupus.

To learn more about the current portfolio of ongoing clinical trials being conducted within LuCIN: http://bit.ly/lucinstudies

09/16/2019

At Lupus Therapeutics, we’re on a mission to accelerate drug discovery and diagnostic innovation for all those living with lupus.

We collaborate with industry, matching our unprecedented clinical trial network of 57 sites with the most important lupus trials led by the biotechnology and pharmaceutical industry.

We catalyze bold risk-taking, incentivizing investigator-initiated trials that will bring real therapies to real patients.

We lead an interdisciplinary dialogue, placing patient voice at the center of strategic planning with the most creative clinicians and scientists in the world.

Together, we will eradicate the debilitating effects of , helping patients live longer, and live better.

Learn more: lupustherapeutics.org

08/30/2019

The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors. Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – to accelerate new ways to diagnose and treat lupus.

Dr. Wallace commented on his new appointment: “Lupus Therapeutics is the most relevant initiative that engages academically based lupus cohorts as part of a collaborative effort to accelerate the development of agents to treat SLE that will make a difference in managing this disorder.”

Read more:

The Lupus Research Alliance affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.

08/21/2019

A new drug takes about 15 years from discovery to approval by the FDA. Out of 10,000 possible drugs discovered, only about five show enough promise to make it through clinical trials. And only about one of those five are safe and effective enough to be approved as a new treatment. That’s why Lupus Therapeutics formed a network of sites throughout North America to test more drugs for lupus and speed up the process to approval.

08/06/2019

Al Roy, Executive Director of Lupus Research Alliance affiliate Lupus Therapeutics explains why Lupus Therapeutics exists and its goals as an organization in managing Lupus Clinical Investigators Network (LuCIN) to improve the lives of those with lupus.

07/18/2019

Caroline Donovan, Manager of Patient Engagement at Lupus Therapeutics spoke at the DIA 2019 meeting about finding ways to make sure diverse groups of patients can make informed choices about joining clinical trials. Read more:

Caroline Donovan, of Lupus Therapeutics spoke at the DIA 2019 meeting about finding ways so diverse patients can learn about clinical trials.